Aromatase inhibitors as adjuvant therapy for breast cancer

被引:0
作者
Maass, N [1 ]
Jonat, W [1 ]
机构
[1] Univ Kiel, Frauenklin, D-24098 Kiel, Germany
来源
GYNAKOLOGE | 2003年 / 36卷 / 02期
关键词
aromatase inhibitor; adjuvant therapy; breast cancer;
D O I
10.1007/s00129-002-1319-9
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Aromatase inhibitors are widely accepted for the endocrine therapy of breast carcinoma. By blocking the aromatase enzyme, aromatase inhibitors reduce the synthesis of estrogen and decrease the estrogen levels that account for the proliferation of hormone-sensitive breast cancer. There is a new generation of steroid (Exemestan) and nonsteroid (Anastrozol, Letrozol) aromatase inhibitors that show strong antitumor activity with an acceptable spectrum of side effects. This new generation of aromatase inhibitors is widely accepted as first- and second-line treatment options for advanced breast cance. Although the antiestrogen tamoxifen remains the gold standard for the adjuvant treatment of hormone-responsive breast cancer, new studies predict a likely switch towards aromatase inhibitors in the near future. However, further studies and longer follow-up times of recent studies are needed. This article describes the relevance of aromatase inhibitors for the adjuvant therapy of breast cancer.
引用
收藏
页码:103 / 109
页数:7
相关论文
共 50 条
[41]   Clinical utilities of aromatase inhibitors in breast cancer [J].
Chumsri, Saranya .
INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2015, 7 :493-498
[42]   Aromatase inhibitors for breast cancer in postmenopausal women [J].
Campos, SM .
ONCOLOGIST, 2004, 9 (02) :126-136
[43]   Appraising adjuvant aromatase inhibitor therapy [J].
Perez, Edith A. .
ONCOLOGIST, 2006, 11 (10) :1058-1069
[44]   Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network [J].
Aiello, Erin J. ;
Buist, Diana S. M. ;
Wagner, Edward H. ;
Tuzzio, Leah ;
Greene, Sarah M. ;
Lamerato, Lois E. ;
Field, Terry S. ;
Herrinton, Lisa J. ;
Haque, Reina ;
Hart, Gene ;
Bischoff, Kimberly J. ;
Geiger, Ann M. .
BREAST CANCER RESEARCH AND TREATMENT, 2008, 107 (03) :397-403
[45]   Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network [J].
Erin J. Aiello ;
Diana S. M. Buist ;
Edward H. Wagner ;
Leah Tuzzio ;
Sarah M. Greene ;
Lois E. Lamerato ;
Terry S. Field ;
Lisa J. Herrinton ;
Reina Haque ;
Gene Hart ;
Kimberly J. Bischoff ;
Ann M. Geiger .
Breast Cancer Research and Treatment, 2008, 107 :397-403
[46]   Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective [J].
Conte, PierFranco ;
Frassoldati, Antonio .
BREAST JOURNAL, 2007, 13 (01) :28-35
[47]   The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results [J].
Yoshimi Ouchi ;
Katsuhiko Nakatsukasa ;
Koichi Sakaguchi ;
Midori Morita ;
Hiroshi Koyama ;
Takayuki Matsuda ;
Makoto Kato ;
Eiichi Konishi ;
Hisako Ono ;
Tetsuya Taguchi .
Journal of Bone and Mineral Metabolism, 2021, 39 :224-229
[48]   The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results [J].
Ouchi, Yoshimi ;
Nakatsukasa, Katsuhiko ;
Sakaguchi, Koichi ;
Morita, Midori ;
Koyama, Hiroshi ;
Matsuda, Takayuki ;
Kato, Makoto ;
Konishi, Eiichi ;
Ono, Hisako ;
Taguchi, Tetsuya .
JOURNAL OF BONE AND MINERAL METABOLISM, 2021, 39 (02) :224-229
[49]   Adjuvant therapy of breast cancer [J].
Kaklamani, VG ;
Gradishar, WJ .
CANCER INVESTIGATION, 2005, 23 (06) :548-560
[50]   Adjuvant therapy for breast cancer [J].
Ridwelski, K ;
Fahlke, J .
ZENTRALBLATT FUR CHIRURGIE, 1998, 123 :142-146